Who Paid My Doc
Sara Spartz
Nurse Practitioner, Primary Care Sioux Falls, SD Nurse Practitioner
NPI 1093457632 CMS profile 11350268
1301 S Cliff Ave Ste 601, Sioux Falls, SD 57105
General payments
$21
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sara Spartz of Sioux Falls, SD is reported in the CMS Open Payments database as having received $21 across 1 general payment and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 7th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $21 | 1 |
Beside peers
- Sara Spartz
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Sara Spartz were reported at $21. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Sara Spartz | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $137 | $39–$445 | $132 |
| 2022 | $0 | $139 | $44–$421 | $149 |
| 2023 | $0 | $163 | $53–$481 | $160 |
| 2024 | $0 | $176 | $54–$511 | $164 |
| 2025 | $21 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 18 drugsPart D claims
460
Drug cost
$152,958
Branded share of claims
60.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 57 | $46,920 | |
| Nucala Mepolizumab | Brand | 12 | $39,149 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 43 | $18,185 | |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | Brand | 24 | $14,593 | |
| Advair Hfa Fluticasone Propion/Salmeterol | Brand | 29 | $13,229 | |
| Incruse Ellipta Umeclidinium Bromide | Brand | 23 | $7,723 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 15 | $7,562 | |
| Roflumilast | Generic | 35 | $1,833 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 14 | $1,310 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 50 | $1,033 |
The 10 drugs with the highest cost, of 18 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$22,317
Medicare patients
251
Services billed
562
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 49% | |
| COPD | 37% | |
| Diabetes | 34% | |
| Ischemic heart disease | 31% | |
| Depression | 30% | |
| Chronic kidney disease | 27% | |
| Heart failure | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Primary Care in South Dakota
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in South Dakota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.